Termination of acute stroke studies involving selfotel treatment

Lancet

Volumn 349, Issue 9044, 1997, Pages 32-

  Davis, Stephen M ^a   Albers, Gregory W ^a   Diener, Hans Christoph ^a   Lees, Kennedy R ^a   Norris, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BRAIN EDEMA; BRAIN INJURY; BRAIN PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0343472092     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62166-6     Document Type: Article

References (5)

1. Markabi S. Selfotel (CGS 19755): the preliminary clinical experience. In: Krieglstein J, Oberpichler-Schwenk H, eds. Pharmacology of cerebral ischemia. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1994:635-42.
2. Grotta J, Clark W, Coull B, et al. Safety and tolerability of glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke 1995; 26: 602-05.
3. Clark WM, et al. Randomized trial of CGS 19755, a glutamate antagonist, in acute ischemic stroke treatment. Neurology 1994; 44 (suppl 2): A270.
4. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in stroke-background and study protocol. Stroke 1985; 16: 885-90.
5. Spiegelhalter DJ, et al. Monitoring clinical trials: conditional or predictive power? Control Clin Trials 1986; 7: 8-17.